Chimerix (NASDAQ:CMRX) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.09, Fidelity Earnings reports. Chimerix had a negative net margin of 1,582.64% and a negative return on equity of 34.94%. The business had revenue of $0.37 million during the quarter, compared to analyst estimates of $0.97 million.

Shares of CMRX traded down $0.17 during mid-day trading on Friday, hitting $3.32. 84,193 shares of the company traded hands, compared to its average volume of 215,341. Chimerix has a 1-year low of $3.11 and a 1-year high of $5.94. The company has a market cap of $172.41 million, a P/E ratio of -2.20 and a beta of 1.20.

Several research firms have recently issued reports on CMRX. Zacks Investment Research downgraded shares of Chimerix from a “buy” rating to a “hold” rating in a report on Tuesday, August 14th. Cowen restated a “hold” rating and set a $6.00 price objective on shares of Chimerix in a report on Thursday, October 18th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Chimerix in a report on Friday, September 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. Chimerix has an average rating of “Hold” and an average target price of $6.75.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN increased its holdings in shares of Chimerix by 46.1% during the first quarter. Wells Fargo & Company MN now owns 33,569 shares of the biopharmaceutical company’s stock valued at $175,000 after acquiring an additional 10,598 shares in the last quarter. Leisure Capital Management acquired a new position in shares of Chimerix during the third quarter valued at about $108,000. Millennium Management LLC increased its holdings in shares of Chimerix by 12.3% during the second quarter. Millennium Management LLC now owns 284,624 shares of the biopharmaceutical company’s stock valued at $1,355,000 after acquiring an additional 31,091 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in Chimerix by 18.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 223,189 shares of the biopharmaceutical company’s stock worth $1,063,000 after buying an additional 35,216 shares during the period. Finally, BlackRock Inc. increased its holdings in Chimerix by 1.7% in the 2nd quarter. BlackRock Inc. now owns 3,496,177 shares of the biopharmaceutical company’s stock worth $16,643,000 after buying an additional 59,554 shares during the period. Hedge funds and other institutional investors own 71.85% of the company’s stock.

WARNING: “Chimerix (CMRX) Releases Quarterly Earnings Results” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://theolympiareport.com/2018/11/10/chimerix-cmrx-releases-quarterly-earnings-results.html.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Recommended Story: What do I need to know about analyst ratings?

Earnings History for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.